IVA — Inventiva SA Share News
0.000.00%
Last trade - 00:00- €669.85m
- €502.00m
- €4.48m
French and Benelux stocks-Factors to watch
Brief: Inventiva Says Co's Partner Sino Biopharm Received IND Approval To Initiate Clinical Trial With Lanifibranor In China
Brief: Inventiva Reports Cash And Cash Equivalents At EUR 56.3 Mln As Of March 31, 2023
Brief: Inventiva Reports Its 2022 Full-Year Results
Brief: Inventiva Reports Preliminary Financial Results For Full-Year 2022¹
Brief: Inventiva Reports Rev For FY 2022 Amounted To €12.2 Mln
Brief: Inventiva Announces Changes To The Clinical Development Of Lanifibranor
Brief: Inventiva Announces Changes To The Clinical Development Of Lanifibranor, Including Plans For A New Phase III Trial In Patients With Nash And Compensated Cirrhosis
Brief: Inventiva Draws Down EUR 25 Mln Under EIB Finance Contract
Brief: Inventiva Secures A New Patent Expanding Ip Protection Of Its Lead Product Candidate Lanifibranor In The US
Brief: Inventiva Secures A New Patent Expanding The IP Protection Of Its Lead Product Candidate Lanifibranor In The U.S.
Brief: Inventiva 9-Month Revenue Down At 0.1 Million Euros
Brief: Inventiva Says Its R&D Capabilities And Objectives Remain Unaltered
Europe Research Roundup: Kardex Holding AG, Mediobanca, Segro
Brief: Inventiva End-June Net Operating Loss Widens To EUR 33.5 Mln
Brief: Inventiva, Sino Biopharm Report Licensing And Collaboration Agreement
Brief: Inventiva End-June Cash Position At EUR 87.2 Mln
Brief: Inventiva Announces Screening Of First Patient In Phase IIa Combination Trial With Lanifibranor, Empagliflozin
Brief: Inventiva Increases Capital By Around EUR 14.6 Mln